About Tracey Lodie

Dr. Lodie joined Quell in July 2021 bringing more than 20 years of experience in the biopharmaceutical industry focused on the discovery and development of cell therapies and novel biologics in the areas of autoimmunity, transplant biology and immune-oncology. She joins from Gamida Cell, a clinical-stage, Nasdaq-listed cell therapy company, where she served as CSO with responsibility for strategic oversight of its cell therapy pipeline and overseeing translational research for clinical programs.

Prior to this, Dr. Lodie served as SVP, translational immunology at BlueRock Therapeutics, where she helped to advance its universal pluripotent stem cell (PSC) platform into multiple therapeutic areas; and as VP of immunology at Syros Pharmaceuticals, where she developed new autoimmunity and immuno-oncology research programs. She also spent 15 years at Sanofi-Genzyme and was instrumental in advancing several development programs through regulatory approval in the areas of transplant and autoimmunity.

Dr. Lodie completed postdoctoral work in hematology/oncology at Harvard Medical School. She holds a Ph.D. in immunology and pathology from Boston University School of Medicine and a B.S. in biology from Fairfield University.